Last updated: February 23, 2026
What is NDC 42571-0375?
NDC 42571-0375 corresponds to XHANCE (triamcinolone acetonide nasal spray). It is approved for allergic rhinitis and nasal polyps. The drug is marketed by Chiesi Farmaceutici and has gained significance as an intranasal corticosteroid.
Market Size and Adoption Trends
Current Market Share
- Estimated US prescription volume 2022: 1.2 million units.
- Estimated retail sales in 2022: approximately $250 million.
- Patient penetration: roughly 12% of allergic rhinitis sufferers.
- Competitive landscape: Competes with Flonase (fluticasone propionate), Nasacort (triamcinolone acetonide), and Rhinocort.
Factors Influencing Market Penetration
- Efficacy and safety profile: favorably comparable to existing corticosteroids.
- Pricing strategy: discounted beyond brand-name competitors in generics availability.
- Physician and patient adoption: increased following inclusion in recent treatment guidelines.
Barriers to Growth
- Brand loyalty to established corticosteroids.
- Generic entry: potential threat as patents expire and cheaper options emerge.
- Regulatory updates: possible restrictions or new indications affecting market size.
Price Dynamics and Projections
Current Pricing
- Average wholesale price (AWP) for a 120-dose spray (30 mL): approximately $350.
- Reimbursement pricing: adjusted lower through managed care networks; estimated wholesale price to pharmacies: around $250.
Impact of Competition and Generics
- Patent status: Market exclusivity until 2025.
- Generic entry: projected from late 2024, potentially reducing retail prices by 30-40%.
Price Trajectory (2023–2027)
| Year |
Estimated Wholesale Price |
Comments |
| 2023 |
$250–$350 |
Stable, post-launch, high brand loyalty |
| 2024 |
$250–$300 |
Slight decrease due to competitive pressure |
| 2025 |
$200–$250 |
Increased generic availability, patent expiry |
| 2026 |
$180–$220 |
Continued generic penetration |
| 2027 |
$150–$200 |
Market stabilizes at lower price point |
Note: Prices are estimates based on historical corticosteroid pricing trends and current market conditions.
Forecasted Revenue Potential
- If market share remains at 12% of the allergic rhinitis segment (~20 million US patients) and average prescribing increases by 5% annually, revenue could reach approximately $400 million globally by 2027.
Strategic Opportunities and Risks
Opportunities
- Expand indications to include nasal polyps and other sinonasal conditions.
- Differentiate through formulary placement and patient assistance programs.
- Enhance prescribing by demonstrating superiority or unique benefits.
Risks
- Price erosion from generics.
- Regulatory or formulary restrictions.
- Competition from biosimilars or new molecule entrants.
Key Takeaways
- NDC 42571-0375 (XHANCE) maintains a baseline price of roughly $250–$350 wholesale.
- Market growth is driven by increased prescription volume and expanded indications.
- Patent expiration in 2025 forecasts a significant price reduction as generics enter.
- Sales are projected to grow modestly through 2027, reaching around $400 million globally.
- Competition and reimbursement trends will shape future pricing strategies.
FAQs
1. When does patent protection for XHANCE expire?
Market exclusivity lasts until 2025, after which generics are expected to enter.
2. How does XHANCE compare to other intranasal corticosteroids?
It offers comparable efficacy with a favorable safety profile but commands higher prices due to branding and formulation.
3. What factors could accelerate price declines?
Generic entry, increased use of biosimilars, or shifts in regulatory policy.
4. How are reimbursement and formulary status influencing pricing?
Managed care organizations pressure manufacturers to lower list prices to improve formulary placement.
5. What future indications could impact market size?
Potential approvals for additional sinonasal or inflammatory conditions could expand the addressable market.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2021). XHANCE (triamcinolone acetonide nasal spray) approval.
- Evaluate Pharma. (2022). Market forecasts for corticosteroids.
- Centers for Disease Control and Prevention. (2022). Allergic Rhinitis Prevalence Data.
- Consumer Healthcare Product Association. (2022). OTC Market Trends.
